Clinical Trial Update: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating the inhalation suspension TQC3721 in patients with moderate to severe chronic obstructive pul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TQC3721 Suspension for Inhalation (TQC3721)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED